Cargando…
Plasma Pro‐Endothelin‐1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism
BACKGROUND: Endothelin 1 (ET‐1) contributes to chronic kidney disease (CKD) development and progression, and endothelin receptor antagonists are being investigated as a novel therapy for CKD. The proET‐1 peptides, endothelin‐like domain peptide (ELDP) and C‐terminal pro‐ET‐1 (CT‐proET‐1), are both p...
Autores principales: | Dhaun, Neeraj, Yuzugulen, Jale, Kimmitt, Robert A., Wood, Elizabeth G., Chariyavilaskul, Pajaree, MacIntyre, Iain M., Goddard, Jane, Webb, David J., Corder, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392442/ https://www.ncbi.nlm.nih.gov/pubmed/25801761 http://dx.doi.org/10.1161/JAHA.114.001624 |
Ejemplares similares
-
Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1
por: Yuzugulen, Jale, et al.
Publicado: (2017) -
Endothelin
por: Davenport, Anthony P., et al.
Publicado: (2016) -
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
por: Farrah, Tariq E., et al.
Publicado: (2019) -
First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis
por: Hunter, Robert W., et al.
Publicado: (2017) -
Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease
por: Anand, Atul, et al.
Publicado: (2020)